Pennsylvania

Global health R&D delivers for Pennsylvania

Click here to select a new state

Select a new state

US government investment in global health R&D has delivered

$1.2 billion

to Pennsylvania research institutions

14,600+ new jobs

for Pennsylvania

Pennsylvania's top USG-funded global health R&D institutions

Magee-Womens Research Institute & Foundation

$318.6 million

University of Pennsylvania

$296 million

University of Pittsburgh

$172.2 million

Pennsylvania State University

$73.7 million

Drexel University

$43 million

Thomas Jefferson University

$40.5 million

Wistar Institute

$34.1 million

Undisclosed PA-based industry recipient

$27.3 million

OraSure Technologies

$26.9 million

Integral Molecular

$22.3 million

VGX Pharmaceuticals (formerly Viral Genomix)*

$20.9 million

Venatorx Pharmaceuticals

$16.5 million

Children's Hospital of Philadelphia

$16 million

Inovio Pharmaceuticals Inc.

$7.5 million

Fox Chase Chemical Diversity Center Inc. (FCCDC)

$6.2 million

Temple University

$5.1 million

Lubrizol Life Science Health (formerly Particle Sciences)

$4.9 million

Baruch S. Blumberg Institute

$4.7 million

Phelix Therapeutics

$4.2 million

Fox Chase Cancer Center

$4 million

HealthVerity

$3.8 million

Instadiagnostics

$3.7 million

PolyMedix Inc.*

$2.6 million

CytoAgents

$2.1 million

Duquesne University

$1.6 million

Lehigh University

$1.5 million

Microbicide Trial Network

$1.1 million

Conifer Point Pharmaceuticals*

$1 million

Vital Probes Inc.*

$1 million

Bucknell University

$970 thousand

Philadelphia Research and Education Foundation

$789 thousand

AlphaThera

$754 thousand

Lifeware Labs LLC

$655 thousand

TB Biosciences*

$638 thousand

Monell Chemical Senses Center

$621 thousand

Qrumpharma*

$606 thousand

Carnegie Mellon University

$525 thousand

University of Pittsburgh Medical Center (including Pittsburgh Children's Hospital)

$502 thousand

Immunotope Inc.*

$408 thousand

Achillion Pharmaceuticals*

$403 thousand

Enantigen Therapeutics Inc.*

$385 thousand

Swarthmore College

$372 thousand

Abzyme Therapeutics LLC

$343 thousand

Vironika LLC

$341 thousand

Vaxform LLC

$324 thousand

JBS Science

$305 thousand

Villanova University

$301 thousand

Infini Fluidics

$293 thousand

Molecular Targeting Technologies Inc.

$256 thousand

Pennsylvania Drug Discovery Institute (PDDI)

$251 thousand

Sonitu Pharmaceuticals*

$195 thousand

Lenima Field Diagnostics

$185 thousand

Pittsburg State University

$185 thousand

Evrys Bio LLC

$175 thousand

Lipella Pharmaceuticals Inc.

$126 thousand

Transwall Office Systems

$116 thousand

Knoll International

$55 thousand

Pennsylvania's top areas of global health R&D by USG funding

3.5%

COVID-19

Diarrheal diseases

Flioviral diseases (including Ebola, Marburg)

47.9%

HIV/AIDS

9.4%

Malaria

7.4%

Neglected tropical diseases

Dengue

Helminth infections (Worms & Flukes)

Kinetoplastid diseases

Trachoma

3.4%

Reproductive health

7.2%

Tuberculosis

2.4%

Zika

8.7%

Other

Arenaviral hemorrhagic fevers (including Lassa fever)

Bacterial pneumonia & meningitis

Bunyaviral diseases (including CCHF, RVF, SFTS)

Chikungunya

Emergent non-polio enteroviruses (including EV71, D68)

Henipaviral diseases (including Nipah)

Hepatitis B

Hepatitis C

Multi-disease/health area R&D

Other coronaviruses (including MERS, SARS)

Rheumatic fever

Salmonella infections

Neglected and emerging diseases in Pennsylvania

Chikungunya cases

275

Dengue cases

381

HIV diagnoses

17278

Malaria cases

1281

Mpox cases

779

Tuberculosis cases

4993

Viral hemorrhagic fevers cases

Global health R&D at work in Pennsylvania

University of Pittsburgh researchers are studying whether bacteria-killing viruses, known as bacteriophages, can be used to treat bacterial infections, including those that are resistant to existing antibiotics. Bacteriophages, or phages for short, are viruses that are harmless to humans but kill bacteria by injecting their DNA into bacterial cells. The Pitt researchers have found success in using phage therapy to treat, under compassionate use protocol, a small number of patients with infections from mycobacterium, a family of bacteria that can be deadly to patients with compromised immune systems. Antibiotic drug resistance is a growing global challenge. Phage therapies offer promise as a new tool that could be used as a replacement to or in tandem with existing antibiotics to improve treatment outcomes.

Footnotes

Methodology
US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
*Organization appears to be closed/out of business.
Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
Case study photo: PATH/Scott Areman